Loss of Mediator complex subunit 13 (MED13) promotes resistance to alkylation through cyclin D1 upregulation

Alkylating drugs are among the most often used chemotherapeutics. While cancer cells frequently develop resistance to alkylation treatments, detailed understanding of mechanisms that lead to the resistance is limited. Here, by using genome-wide CRISPR–Cas9 based screen, we identify transcriptional M...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nucleic Acids Res
Autores principales: Roliński, Miłosz, Montaldo, Nicola Pietro, Aksu, Merdane Ezgi, Fordyce Martin, Sarah L, Brambilla, Alessandro, Kunath, Nicolas, Johansen, Jostein, Erlandsen, Sten Even, Liabbak, Nina-Beate, Rian, Kristin, Bjørås, Magnar, Sætrom, Pål, van Loon, Barbara
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2021
Materias:
Genome Integrity, Repair and Replication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7897519/
https://ncbi.nlm.nih.gov/pubmed/33444446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gkaa1289
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares